Medroxyprogesterone acetate (depo‐provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma

M. Steven Piver*, Joseph J. Barlow, John R. Lurain, Leslie E. Blumenson

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

78 Scopus citations


A prospective trial was initiated in 1972 utilizing Depo‐Provera in women with metastatic or recurrent endometrial adenocarcinoma to evaluate if the objective response and survival would be significantly improved in comparison to patients previously treated with Delalutin at a similar dose. One hundred fourteen patients were included in the study: 70 received Delalutin and 44 Depo‐Provera. There was no significant increase in the objective response or survival between the Delalutin or Depo‐Provera patients. Of the 114 patients, 15.8% achieved an objective response, with 7.0% being complete responders. There was no significant increase in objective response to Delalutin or Depo‐Provera in relationship to the size of the tumor masses, the number of metastases, site of metastases, histologic grade of the primary, histologic grade of recurrence or metastases, or prior radiation therapy. The only significant correlate was that patients whose disease recurred 3 or more years after the initial therapy had a significant (P = 0.01) increase in response (33.3%) compared to those with recurrence less than 3 years after their original treatment (8.3%).

Original languageEnglish (US)
Pages (from-to)268-272
Number of pages5
Issue number2
StatePublished - Jan 15 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Medroxyprogesterone acetate (depo‐provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma'. Together they form a unique fingerprint.

Cite this